Genetically Engineered Model Development Service
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons. Research has identified several genes linked to PD, including SNCA, LRRK2, PRKN, PINK1, and GBA1. Genetically engineered models (GEMs) are crucial tools for studying PD pathogenesis, elucidating disease mechanisms, and testing potential therapies. These models, often created using CRISPR/Cas9 technology, replicate key aspects of the disease in laboratory animals, allowing researchers to investigate the complex interplay of genetic and environmental factors. Creative Biolabs' Genetically Engineered Models for PD help you accelerate your research and obtain more physiologically relevant data through advanced CRISPR/Cas9 technology.
How Genetically Engineered Models Can Assist Your Project
Our genetically engineered models for provide you with tailored solutions, delivering precise animal models that accurately mimic the genetic complexities of PD. This enables more effective preclinical research, facilitating the development of targeted therapies and a deeper understanding of disease mechanisms.
Discover How We Can Help - Request a Consultation
Workflow
CBL's workflow is designed to provide a streamlined and efficient process for generating custom genetically engineered models. Here's a detailed look at the key steps involved:
-
Required Starting Materials:
- Specific gene sequence of interest (e.g., SNCA, LRRK2, PRKN).
- Detailed information about the desired genetic modification (e.g., point mutation, knockout, conditional allele).
- Preferred animal species and strain (e.g., mouse, rat).
-
Final Deliverables:
- Detailed characterization report, including genotyping data, phenotypic analysis, and any relevant experimental findings.
- Established line of genetically engineered animals, delivered as live animals or cryopreserved embryos.
- Customized protocols and reagents, if required, to support your ongoing research.
-
Estimated Timeframe:
- The typical timeframe for this service ranges from 26 to 52 weeks, depending on the complexity of the genetic modification, the animal species, and the extent of characterization required.
Why Choose Us?
CBL stands at the forefront of genetically engineered model development, offering unparalleled expertise and cutting-edge technologies to accelerate your research. Our commitment to precision, efficiency, and customer satisfaction ensures that you receive the highest quality models and support.
Experience the CBL Advantage - Get a Quote Today
Genetically Engineered Models For PD
Genetically engineered models are created by introducing specific genetic alterations into an organism's genome. These alterations can include:
- Transgenic models: Overexpression of a gene implicated in PD, such as alpha-synuclein (SNCA).
- Knockout models: Inactivation of a gene, such as parkin (PRKN) or PINK1, to study the effects of its absence.
- Knock-in models: Insertion of a specific disease-causing mutation into the endogenous gene, more accurately mimicking the human condition.
- Conditional models: Allow for spatial and temporal control of gene expression
Customer Reviews
"The precision and reliability of CBL's genetically engineered models have significantly improved our ability to study Parkinson's disease pathogenesis. The detailed characterization data provided was invaluable." Dr. A**a Patel, Neurobiology Institute.
"Using CBL's Genetically Engineered Models for Parkinson's Disease in our research has significantly facilitated the identification of novel therapeutic targets. The turnaround time was also impressive." Dr. M**k Smith, Biotech Innovations.
"CBL's expertise in CRISPR/Cas9 technology and their ability to generate complex models have greatly enhanced our understanding of gene function in Parkinson's disease. The support and consultation throughout the process were exceptional." Dr. J**e Brown, University Medical Center.
What we can offer
We offer a comprehensive service for the generation of Genetically Engineered Models for PD, with key advantages including:
- Documentation quality and procedures of strain origin are assessed and approved by a qualified quality assurance service.
- We guarantee the stability of strains in cell banks and large-scale in vivo model generation, including initial model creation and subsequent breeding.
- We optimize the codon usage of genes to facilitate expression in selected animal models.
- We offer flexibility in model generation, including traditional transgenic approaches and advanced gene editing.
- We optimize in vivo model conditions to maximize the efficiency and relevance of the model.
- High-standard quality control tools are employed to quantify and evaluate the quality and reliability of our genetically engineered models.
Related Services
CBL offers a comprehensive suite of related services to support your Parkinson's disease research:
- Gene Synthesis: For generating DNA constructs with high accuracy.
- Cell Line Engineering: To create cell-based models of PD.
- Protein Expression and Purification: For producing high-quality recombinant proteins.
FAQs
Q How can CBL's genetically engineered models help me study specific Parkinson's disease-related genes?
Q What are the advantages of using CBL's models compared to other PD models?
Q Can CBL generate custom models tailored to my specific research needs?
Q What kind of support and data does CBL provide with its models?
Q How long does it take to generate a genetically engineered model with CBL?
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1686) (Cat#: NRP-0422-P1686)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Anti-TNFα BBB Shuttle Antibody (NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2293) (Cat#: NRP-0422-P2293)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- Human Brain Vascular Adventitial Fibroblasts (Cat#: NCL-21P6-014)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Green Fluorescent Tau cell Line (Cat#: NCL2110P219)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)